Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a large increase in short interest in November. As of November 15th, there was short interest totalling 8,000 shares, an increase of 300.0% from the October 31st total of 2,000 shares. Based on an average daily trading volume, of 18,100 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.1% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reduced their price objective on Cocrystal Pharma from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, August 22nd.

Cocrystal Pharma Stock Down 0.9 %

NASDAQ:COCP traded down $0.02 during trading hours on Wednesday, hitting $2.10. 6,018 shares of the stock were exchanged, compared to its average volume of 21,091. The company’s 50 day moving average is $1.88 and its two-hundred day moving average is $2.03. Cocrystal Pharma has a twelve month low of $1.33 and a twelve month high of $3.10. The company has a market capitalization of $21.36 million, a P/E ratio of -1.15 and a beta of 1.45.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.